Keros Therapeutics, Inc. $KROS Position Boosted by Y Intercept Hong Kong Ltd

Y Intercept Hong Kong Ltd lifted its holdings in Keros Therapeutics, Inc. (NASDAQ:KROS) by 40.2% during the 1st quarter, HoldingsChannel.com reports. The firm owned 164,483 shares of the company’s stock after acquiring an additional 47,122 shares during the quarter. Y Intercept Hong Kong Ltd’s holdings in Keros Therapeutics were worth $1,816,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Financial Management Professionals Inc. bought a new stake in Keros Therapeutics during the fourth quarter worth approximately $29,000. Caitong International Asset Management Co. Ltd increased its holdings in shares of Keros Therapeutics by 254.6% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,624 shares of the company’s stock valued at $33,000 after buying an additional 1,166 shares in the last quarter. Tower Research Capital LLC TRC lifted its position in shares of Keros Therapeutics by 149.2% during the 2nd quarter. Tower Research Capital LLC TRC now owns 3,153 shares of the company’s stock valued at $42,000 after acquiring an additional 1,888 shares during the last quarter. New York State Common Retirement Fund lifted its position in shares of Keros Therapeutics by 264.1% during the 2nd quarter. New York State Common Retirement Fund now owns 10,616 shares of the company’s stock valued at $142,000 after acquiring an additional 7,700 shares during the last quarter. Finally, The Manufacturers Life Insurance Company lifted its position in shares of Keros Therapeutics by 8.6% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 12,451 shares of the company’s stock valued at $166,000 after acquiring an additional 988 shares during the last quarter. 71.56% of the stock is currently owned by institutional investors.

Insider Activity

In related news, Director Nima Farzan sold 2,625 shares of the business’s stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $10.73, for a total value of $28,166.25. Following the completion of the sale, the director owned 9,767 shares of the company’s stock, valued at approximately $104,799.91. The trade was a 21.18% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Julius Knowles sold 2,625 shares of the stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $10.73, for a total value of $28,166.25. Following the completion of the transaction, the director owned 10,958 shares in the company, valued at $117,579.34. This represents a 19.33% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 8,425 shares of company stock worth $89,994 in the last three months. 20.60% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on KROS shares. Wall Street Zen cut Keros Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday, May 16th. Weiss Ratings downgraded Keros Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a report on Friday, May 15th. Three equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $20.40.

Keros Therapeutics Trading Up 3.1%

KROS opened at $12.03 on Friday. The stock has a market cap of $238.07 million, a price-to-earnings ratio of -4.00 and a beta of 0.97. Keros Therapeutics, Inc. has a 1 year low of $9.69 and a 1 year high of $22.55. The stock has a fifty day moving average price of $10.95 and a 200 day moving average price of $13.72.

Keros Therapeutics (NASDAQ:KROS) last issued its earnings results on Thursday, May 14th. The company reported ($1.21) earnings per share for the quarter, missing the consensus estimate of ($1.02) by ($0.19). Keros Therapeutics had a negative return on equity of 17.04% and a negative net margin of 256.60%.The firm had revenue of $0.37 million during the quarter, compared to analyst estimates of $1.93 million. As a group, sell-side analysts forecast that Keros Therapeutics, Inc. will post -5.19 earnings per share for the current fiscal year.

Keros Therapeutics Profile

Keros Therapeutics, Inc (NASDAQ: KROS) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company’s research centers on modulating the transforming growth factor-beta (TGF-?) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need.

The company’s lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis.